KARO BIO’S CEO BUYS SHARES IN THE COMPANY

STOCKHOLM, March 29, 2010. Karo Bio AB (publ) (Reuters: KARO.ST) today announced that the new President and CEO Fredrik Lindgren today has bought 500,000 shares in the company.

Fredrik Lindgren, President and CEO of Karo Bio, has during today’s trading at the OMX NASDAX Stockholm Exchange bought 500,000 shares in Karo Bio. The holding of 500,000 shares corresponds to 0.3% of the total number of shares in the company. For further information please contact: Erika Söderberg Johnson, CFO Phone: +46 8 608 60 52 Karo Bio may be required to disclose the information provided herein pursuant to the Swedish Securities Markets Act and/or the Swedish Financial Instruments Trading Act. The information was published on April 28, 2010 at 2:30pm CET. About Karo Bio Karo Bio is a drug discovery and development company specializing in endocrinology and targeting nuclear receptors as target proteins for the development of novel pharmaceuticals. The company has a project portfolio with innovative molecules that primarily target dyslipidemia, CNS-disorders, inflammation, and women’s health. In these areas, there are significant market opportunities and a clear need for pharmaceuticals with new mechanisms of action. Karo Bio has the capacity to bring selected compounds in therapeutic niche areas into late stage clinical development and, potentially, registration, while the intention is to out-license compounds aimed at treating broad patient populations at the latest when clinical proof-of-concept has been obtained in clinical phase II-studies. In addition to the proprietary projects, Karo Bio has three strategic collaborations with international pharmaceutical companies for development of innovative therapies for the treatment of common diseases. Karo Bio is listed on NASDAQ OMX Stockholm since 1998 (Reuters: KARO.ST). This press release is also available online at: www.karobio.com and www.newsroom.cision.com